Goodman and Gilman Award in Drug Receptor Pharmacology

Goodman and Gilman Award in Drug Receptor Pharmacology. This prestigious award is presented by the American Society for Pharmacology and Experimental Therapeutics to honor exceptional contributions to the field of drug receptor pharmacology. It commemorates the legacy of Louis S. Goodman and Alfred Gilman Sr., the pioneering authors of the seminal textbook Goodman & Gilman's The Pharmacological Basis of Therapeutics. The award recognizes scientists whose work has significantly advanced the understanding of receptor mechanisms, signal transduction, and drug discovery.

History and background

The award was established in 1990 by a generous endowment from the Burroughs Wellcome Fund, a foundation with a long history of supporting biomedical research. Its creation was a direct tribute to the monumental influence of Louis S. Goodman and Alfred Gilman Sr., whose collaborative work defined modern pharmacology. Their textbook, first published in 1941, systematically organized pharmacological knowledge around therapeutic applications and mechanisms of drug action, fundamentally shaping medical education and research at institutions like Yale University and the University of Virginia. The establishment of this award coincided with rapid advancements in molecular biology and the cloning of numerous G protein-coupled receptors, cementing the central role of receptor pharmacology in the pharmaceutical industry and National Institutes of Health-funded research.

Award criteria and nomination process

Eligibility for the award is restricted to scientists who are members of the American Society for Pharmacology and Experimental Therapeutics and have conducted seminal research in drug receptor pharmacology. The nomination process requires a detailed letter of recommendation outlining the candidate's transformative contributions, a comprehensive curriculum vitae, and a list of key publications. A critical criterion is the demonstration of a sustained and impactful research program that has elucidated fundamental principles of ligand-receptor interactions, allosteric regulation, or receptor desensitization. The selection is made by a dedicated award committee within the American Society for Pharmacology and Experimental Therapeutics, which evaluates the nominee's influence on both basic science and therapeutic development, often evidenced by citations, patents, or clinical applications.

Recipients and notable contributions

Recipients of the award constitute a distinguished group of pharmacologists whose discoveries have been foundational. Early awardees include pioneers like Robert J. Lefkowitz of Duke University, honored for his Nobel Prize-winning work on G protein-coupled receptors, and Paul Greengard of Rockefeller University, recognized for his research on dopamine receptor signaling. Other notable recipients include Terry Kenakin, known for his theories on receptor theory and biased agonism, and Marc G. Caron, for his elucidation of dopamine receptor structure and function. The work of these scientists, often conducted at major research centers like the National Institute of Mental Health or Stanford University, has directly informed drug development for conditions ranging from hypertension to schizophrenia.

Significance and impact in pharmacology

The Goodman and Gilman Award holds substantial significance as a benchmark for excellence in a core discipline of pharmacology. It highlights research that bridges the gap between molecular mechanisms and therapeutic efficacy, a principle central to the textbook's philosophy. Award-recognized work has directly impacted the development of major drug classes, including beta blockers, antipsychotics, and SSRIs. By honoring investigators at institutions such as the Mayo Clinic and Johns Hopkins University, the award reinforces the importance of receptor pharmacology in understanding disease pathways at organizations like the World Health Organization and guiding research funding from bodies like the National Science Foundation.

Administration and sponsoring organizations

The award is administered entirely by the American Society for Pharmacology and Experimental Therapeutics, a leading professional society founded in 1908. The initial endowment from the Burroughs Wellcome Fund provides the financial foundation for the prize, which includes a monetary award and an invitation to deliver a special lecture at the society's annual meeting, often held in conjunction with the Experimental Biology conference. Oversight is provided by the American Society for Pharmacology and Experimental Therapeutics Awards Committee, which ensures the award's criteria align with the evolving landscape of pharmacological science. The enduring partnership between the society and the philanthropic legacy of the Burroughs Wellcome Fund sustains the award's prestige and its role in promoting innovation in biomedical research.

Category:Medical and health awards Category:Pharmacology awards Category:American Society for Pharmacology and Experimental Therapeutics